Stockscreener 앱 받기
141.77
2.72%
3.76
시간 외 거래:
141.78
0.010
+0.01%
Palvella Therapeutics Inc 주식(PVLA)의 최신 뉴스
Palvella Therapeutics Inc (PVLA) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Palvella Therapeutics Inc (PVLA) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
PVLA|Palvella Therapeutics Inc|Price:138.010|Chg%:-5.195 - TradingKey
TradingKey - TradingKey
Palvella Therapeutics, Inc. Revenue Breakdown – NASDAQ:PVLA - TradingView
Palvella Therapeutics Inc (PVLA) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Palvella Therapeutics Inc (PVLA) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Enterprise value to revenue forward of Palvella Therapeutics, Inc. – FWB:PI6 - TradingView
H.C. Wainwright reiterates Palvella Therapeutics stock rating at buy - Investing.com UK
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Palvella Therapeutics (PVLA), Neogen (NEOG) and ACADIA Pharmaceuticals (ACAD) - The Globe and Mail
Analysts Have Conflicting Sentiments on These Healthcare Companies: Palvella Therapeutics (PVLA), Neogen (NEOG) and ACADIA Pharmaceuticals (ACAD) - The Globe and Mail
H.C. Wainwright reiterates Palvella Therapeutics stock rating at buy By Investing.com - Investing.com Nigeria
H.C. Wainwright Maintains Palvella Therapeutics(PVLA.US) With Buy Rating, Maintains Target Price $270 - Moomoo
Oppenheimer Maintains Palvella Therapeutics(PVLA.US) With Buy Rating, Maintains Target Price $210 - Moomoo
BTIG Maintains Palvella Therapeutics(PVLA.US) With Buy Rating, Maintains Target Price $215 - Moomoo
Analysts Offer Insights on Healthcare Companies: Palvella Therapeutics (PVLA) and Armata Pharmaceuticals (ARMP) - The Globe and Mail
Palvella Therapeutics (PVLA) Sees Significant Decline - GuruFocus
Palvella Therapeutics (PVLA) COO exercises options, then sells 4,302 shares - Stock Titan
Palvella Therapeutics Soars On Key FDA Review Break - TipRanks
Palvella Therapeutics COO Kathleen Goin disposes of 4,302 common shares worth $642,194.57 - Bitget
Palvella Therapeutics Files New Drug Application for QTORIN - harianbasis.co
Palvella Therapeutics Highlights Growth Plans and QTORIN Progress - TipRanks
Palvella Therapeutics Files Initial NDA for QTORIN Gel - sekbernews.id
Palvella Therapeutics (PVLA) Submits Initial Module of NDA For QTORIN - Yahoo Finance
Palvella Therapeutics posts corporate presentation highlighting Phase 3 SELVA wins, NDA rolling review and $262M cash - TradingView
Palvella Therapeutics (PVLA) Proxy filing Summary - Quartr
Palvella Therapeutics (PVLA) Faces Pullback After Recent Gains – Key Support Levels in FocusRevenue Growth Stocks - dars.gov.et
Palvella Therapeutics Inc. (PVLA) Stock Price | Live Quotes & Charts | NASDAQ - timothysykes.com
Palvella Adds Rare-Disease Executive to Board Ahead of Launch - MyChesCo
PVLAPalvella Therapeutics Inc Volatility & Greeks - Finviz
Price to book forward of Palvella Therapeutics, Inc. – NASDAQ:PVLA - TradingView
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Bio-Techne (TECH), Concentra Group Holdings Parent, Inc. (CON) and Palvella Therapeutics (PVLA) - The Globe and Mail
Mizuho Securities Maintains Palvella Therapeutics(PVLA.US) With Buy Rating, Maintains Target Price $240 - Moomoo
Palvella Therapeutics Adds Industry Veteran to Board - The Globe and Mail
Palvella Therapeutics (NASDAQ: PVLA) director reports zero share stake - Stock Titan
Palvella Therapeutics Adds Rare Disease Executive Matt Pauls to Board of Directors - citybiz
Palvella Therapeutics, Inc. Files Form 8-K: Key Company Details, Stock Info, and Contact Information (June 2026) - Minichart
Palvella Therapeutics appoints Matt Pauls to board of directors By Investing.com - Investing.com South Africa
Palvella Therapeutics appoints Matt Pauls to board of directors - Investing.com
Palvella Therapeutics Appoints Accomplished Rare Disease Biotech Executive and Commercial Leader Matt Pauls, J.D., M.B.A., to Board of Directors - The Globe and Mail
Palvella Therapeutics Appoints Accomplished Rare Disease - GlobeNewswire
Matthew Pauls joins Palvella Therapeutics (PVLA) board with 6,000-share option grant - Stock Titan
Palvella Therapeutics stock hits 52-week high at 151.36 USD - Investing.com
Palvella Therapeutics stock hits 52-week high at 151.36 USD By Investing.com - Investing.com Nigeria
Palvella Therapeutics, Inc.(NasdaqGM: PVLA) dropped from Russell 3000E Index - marketscreener.com
Palvella Therapeutics, Inc.(NasdaqGM: PVLA) dropped from Russell Microcap Index - marketscreener.com
Palvella submits FDA NDA for QTORIN gel - grafa.com
Palvella submits first module of NDA for rare skin disease therapy - Investing.com
Palvella Therapeutics Submits First Module of Rolling New Drug Application to FDA for QTORIN™ Rapamycin for the Treatment of Microcystic Lymphatic Malformations - The Manila Times
Palvella Therapeutics Submits First Rolling NDA Module for QTORIN Rapamycin in Microcystic Lymphatic Malformations - Quiver Quantitative
Palvella Therapeutics Submits First Module of Rolling New - GlobeNewswire
Palvella Therapeutics, Inc.(NasdaqGM:PVLA) dropped from Russell Small Cap Comp Value Benchmark - marketscreener.com
Palvella Therapeutics, Inc.(NasdaqGM: PVLA) dropped from Russell 3000 Value Benchmark - marketscreener.com
Palvella Therapeutics, Inc.(NasdaqGM: PVLA) dropped from Russell 2500 Value Benchmark - marketscreener.com
Palvella Therapeutics, Inc.(NasdaqGM:PVLA) dropped from Russell 3000E Value Benchmark - marketscreener.com
1.97%
0.83%
자본화:
|
볼륨(24시간):